Effect of DNA conformation on cisplatin adduct formation

Biochemical Pharmacology

Volumn 51, Issue 5, 1996, Pages 717-721

  Bubley, Glenn J ^a   Xu, Jian ^b   Kupiec, Nadav ^a   Sanders, Dennis ^c   Foss, Francine ^c   O'Brien, Mary ^c   Emi, Yasu ^d   Teicher, Beverly A ^d   Patierno, Steven R ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

arginine butyrate; chromatin; cisplatin

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE BUTYRATE; CISPLATIN; TRANSPLATIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CHROMATIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA CONFORMATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0029988724     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(95)02256-2     Document Type: Article

References (27)

1. Loehrer P and Einhorn L, Drugs five years later: Cisplatin. Ann Intern Med 100: 704-713, 1984.
2. Pinto AL and Lippard SJ, Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum(II). Proc Natl Acad Sci USA 82: 4616-4619, 1985.
3. Ling ECH, Allen GW and Hambley TW, DNA binding of a platinum(II) complex designed to bind interstrand but not intrastrand. J Am Chem Soc 116: 2673-2674, 1994.
4. Bubley GJ, Teicher B, Ogata G, Sandovat L and Kusomoto T, Differences in in vivo and in vitro sequence-specific sites of cis-platin-DNA adduct formation and detection of a dose-response relationship. Biochem Pharmacol 48: 145-153, 1994.
5. Foka M and Paoletti J, Interaction of cisplatin to chromatin. Biochem Pharmacol 35: 3283-3291, 1986.
6. Hayes J and Scovell W, Cisplatin modified chromatin and nucleosomal core particle. Biochim Biophys Acta 1089: 377-385, 1991.
7. Gasser SM and Laemmli UK, A glimpse at chromosomal order. Trends Genet 3: 16-22, 1987.
8. Xu J, Manning FCR and Patierno SR, Preferential formation and repair of chromium-induced DNA adducts and DNA-protein crosslinks in nuclear matrix DNA. Carcinogenesis 15: 1443-1450, 1994.
9. Obi FO, Ryan A and Billett MA, Preferential binding of the carcinogen benzo[a]pyrene to DNA in active chromatin and the nuclear matrix. Carcinogenesis 7: 907-913, 1986,
10. Sambrook J, Fritsch EF and Maniatis T, Molecular Cloning: A Laboratory Manual, 2nd Edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
11. Epelbaum R, Teicher BA, Holden S, Ara G, Varshaney A and Herman TS, Interaction of D, L- and D-tetraplatin with hyperthermia in vitro and in vivo. Eur J Cancer 28: 794-800, 1992.
12. Ciejek E, Tsai M and O'Malley N, Actively transcribed genes are associated with the nuclear matrix. Nature 306: 607-609, 1983.
13. Lewin B, Chromatin and gene expression: Constant questions but changing answers. Cell 79: 397-406, 1994.
14. Gewirtz D, Orr M, Fornari F, Randolph J, Yalowich J, Ritke M, Povirk L and Bunch R, Dissociation between bulk damage to DNA and the antiproliferative activity of teniposide (VM-26) in the MCF-7 breast tumor cell line: Evidence for gene-specific damage and alterations in gene expression. Cancer Res 53: 3547-3554, 1993.
15. Sanders D, Tansan S, Arthur V, Faller D, McCaffrey R and Foss F, Phase I clinical trial of arginine butyrate in patients with refractory neoplasms. Am Soc Clin Oncol Proc 14: 476, 1995.
16. Boffa LC, Vidali G, Mann RS and Allfrey VG, Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 253: 3364-3366, 1978.
17. Schlake T, Klehr-Wirth D, Yoshida M, Beppu T and Bode J, Gene expression within a chromatin domain: The role of core histone hyperacetylation. Biochemistry 33: 4197-4206, 1994.
18. Norton VG, Marvin KW, Yau P and Bradbury EM, Nucleosome linking number change controlled by acetylation of histones H3 and H4. J Biol Chem 265: 19848-19852, 1990.
19. Kijima M, Yoshida M, Sugita K, Horinouchi S and Beppu T, Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268: 22429-22435, 1993.
20. Teicher BA, Preclinical models for high dose therapy. In: High Dose Cancer Therapy (Eds. Armitage JO and Antman KH), 2nd Ed, pp. 17-48. Williams & Wilkens, Baltimore, 1995.
21. Pienta K and Coffey D, Correlation of nuclear morphology with the progression of breast cancer. Cancer 68: 2012-2016, 1991.
22. Partin AW, Getzenberg RH, CarMichael MJ, Vindivich D, Yoo J, Epstein JI and Coffey DS, Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 53: 744-746, 1993.
23. Lippard SJ and Hoeschele JD, Binding of cis- and trans-dichlorodiammineplatinum(II) to the nucleosome core. Proc Natl Acad Sci USA 76: 6091-6095, 1979.
24. Ciccarelli RB, Solomon MJ, Varshavsky A and Lippard SJ, In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: Differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry 24: 7533-7540, 1985.
25. Comess K, Burstyn J, Essigmann J and Lippard S, Replication inhibition and translesional synthesis on templates containing site-specific placed cisplatin DNA adducts. Biochemistry 31: 3975-3990, 1992.
26. Bernges F and Holler E, The reaction of platinum(II) complexes with DNA. Kinetics of intrastrand crosslink formation in vitro. Nucleic Acids Res 19: 1483-1489, 1991.
27. Anin M and Leng M, Distortions induced in double-stranded DNA by binding of cisplatin and transplatin to the GTG sequence. Nucleic Acids Res 18: 4395-4400, 1990.